RJA
BMY icon

Ross\Johnson & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Ross\Johnson & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$121 Hold
2
– – ﹤0.01% 196
2025
Q4 		$108 Hold
2
– – ﹤0.01% 303
2025
Q3 		$90 Hold
2
– – ﹤0.01% 203
2025
Q2 		$93 Sell
2
-5
-71% -$245 ﹤0.01% 199
2025
Q1 		$426 Buy
+7
New +$408 0.01% 254

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ross\Johnson & Associates's BMY Position: Q1 2026 in Review

Ross\Johnson & Associates held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 2 shares worth $121. The position accounts for ﹤0.01% of the portfolio, ranked #196.

Ross\Johnson & Associates first reported a position in BMY in Q1 2025 and has held it in 5 quarters since. The position peaked at $426 in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Ross\Johnson & Associates held 2 shares of Bristol-Myers Squibb worth $121 as of Q1 2026.
  • Ross\Johnson & Associates left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q1 2026, its #196 holding.
  • Ross\Johnson & Associates first reported a position in Bristol-Myers Squibb in Q1 2025 and has held it in 5 quarters since.
  • Ross\Johnson & Associates's Bristol-Myers Squibb position peaked at $426 in Q1 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Ross\Johnson & Associates's 13F filing for Q1 2026, filed 8 May 2026.